Ophthalmology Focus Altacor is an ophthalmology specialist with products like Clinitas for dry eye. Following its 2025 acquisition by Fidia Pharma, there is potential to leverage Fidia’s global distribution and clinic network to expand eye care product reach in the UK and Europe.

Licensing Opportunities Historically, Altacor engaged in licensing and distribution partnerships, notably in North America. Post acquisition, there are opportunities to pursue new licensing or co development in additional markets using Fidia’s regulatory footprint and manufacturing capabilities.

Education Initiatives Altacor launched Altacor Hub in 2021 to support disease awareness and education for eyecare. This indicates readiness for education driven product adoption; propose co branded webinars, clinician events, and digital education programs to drive uptake of Clinitas and future ocular products.

Access and Delivery History of patient access initiatives includes a home delivery partnership with Adaro Optics in 2020, showing openness to direct delivery channels. This can be modernized under Fidia to improve access for dry eye therapies through clinic partnerships and patient delivery options.

Growth and Partnerships The company shows modest revenue (0-1M) but has raised about 3.1M in funding, signaling early stage growth. A BD angle is to explore joint investments or strategic licensing with Fidia to accelerate product launches, scale manufacturing, and expand into new geographies.